Dengue dynamics and vaccine cost-effectiveness in Brazil

Vaccine

Volumn 31, Issue 37, 2013, Pages 3957-3961

  Durham, David P ^a   Ndeffo Mbah, Martial L ^a   Medlock, Jan ^b   Luz, Paula M ^c   Meyers, Lauren A ^d   Paltiel, A David ^a   Galvani, Alison P ^a  

^a YALE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Funda??o Oswaldo Cruz   (Brazil)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cost effectiveness; Dengue; Modeling; Vaccine

Indexed keywords

DENGUE VACCINE;

ARTICLE; BRAZIL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENGUE; DISEASE TRANSMISSION; DRUG EFFICACY; HEALTH CARE POLICY; HERD IMMUNITY; HUMAN; MASS IMMUNIZATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VACCINATION;

COST-EFFECTIVENESS; DENGUE; MODELING; VACCINE;

BRAZIL; COST-BENEFIT ANALYSIS; DENGUE; DENGUE VACCINES; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; MODELS, THEORETICAL; VACCINATION;

EID: 84881554687     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.036     Document Type: Article

References (29)

1. Suaya J.A., Shepard D.S., Siqueira J.B., Martelli C.T., Lum L.C.S., Tan L.H., et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009, 80(May (5)):846-855.
2. Shepard D.S., Coudeville L., Halasa Y.A., Zambrano B., Dayan G.H. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 2011, 84(2):200-207.
3. De Simone T.S., Nogueira R.M.R., Araújo E.S.M., Guimarães F.R., Santos F.B., Schatzmayr H.G., et al. Dengue virus surveillance: the co-circulation of DENV-1, DENV-2 and DENV-3 in the State of Rio de Janeiro, Brazil. Trans Roy Soc Trop Med Hyg 2004, 98(September (9)):553-562.
4. De Melo F.L., Romano C.M., De Andrade Zanotto P.M. Introduction of dengue virus 4 (DENV-4) genotype I into Brazil from Asia?. PLoS Negl Trop Dis 2009, 3(January (4)):e390.
5. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Micro 2007, 5(7):518-528.
6. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29(42):7276-7284.
7. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241.
8. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3):370-377.
9. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(September (9853)):1559-1567.
10. Halstead S.B. Dengue vaccine development: a 75% solution?. Lancet 2012, 380(November (9853)):1535-1536.
11. Zorlu G., Fleck F Dengue vaccine roll-out: getting ahead of the game. Bull World Health Organ 2011, 89(July (7)):476-477.
12. Amarasinghe A., Mahoney R.T. Estimating potential demand and supply of dengue vaccine in Brazil. Hum Vaccines 2011, 7(July (7)):776-780.
13. Shepard D.S., Suaya J.A., Halstead S.B., Nathan M.B., Gubler D.J., Mahoney R.T., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 2004, 22(9-10):1275-1280.
14. Shepard D.S., Suaya J.A. Cost-effectiveness of a dengue vaccine in Southeast Asia and panama: preliminary estimates. Handbook of disease burdens and quality of life measures 2010, 1281-1296. Springer, New York, NY. V.R. Preedy, R.R. Watson (Eds.).
15. Lee B.Y., Connor D.L., Kitchen S.B., Bacon K.M., Shah M., Brown S.T., et al. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg 2011, 84(5):764-772.
16. Carrasco L.R., Lee L.K., Lee V.J., Ooi E.E., Shepard D.S., Thein T.L., et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis 2011, 5(12):e1426.
17. Johansson M.A., Hombach J., Cummings D.A.T. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine 2011, 29(35):5860-5868.
18. Ibuka Y., Paltiel A.D., Galvani A.P. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. Med Decis Making 2012, 32(May (3)):442-446.
19. Mahoney R.T., Francis D.P., Frazatti-Gallina N.M., Precioso A.R., Raw I., Watler P., et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012, 30(July (32)):4892-4896.
20. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
21. CIA. CIA - The World Factbook - Brazil [Internet]. [cited 2012 Feb 24]. Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/br.html.
22. Stinnett A.A., Mullahy J. Net health benefits a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18(2):S68-S80.
23. World Bank GDP per capita [Internet]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
24. IMF. World Economic Outlook Database List [Internet]. Available from: http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx.
25. WHO. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, 2001.
26. Barata R.B., Sampaio de Almeida Ribeiro M.C., De Moraes J.C., Flannery B. Socioeconomic inequalities and vaccination coverage: results of an immunisation coverage survey in 27 Brazilian capitals, 2007-2008. J Epidemiol Community Health 2012, 66(October (10)):934-941.
27. Cordeiro M.T., Silva A.M., Brito C.A.A., Nascimento E.J.M., Magalhaes M.C.F., Guimaraes G.F., et al. Characterization of a Dengue Patient Cohort in Recife, Brazil. Am J Trop Med Hyg 2007, 77(December (6)):1128-1134.
28. Balmaseda A., Hammond S.N., Tellez Y., Imhoff L., Rodriguez Y., Saborío S.I., et al. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop Med Int Health 2006, 11(June (6)):935-942.
29. Oliveira M.F., Galvao Araujo J.M., Ferreira O.C., Ferreira D.F., Lima D.B., Santos F.B., et al. Two lineages of dengue virus type 2, Brazil. Emerg Infect Dis 2010, 16(March (3)):576-578.